Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Jul;93(1):1-3.
doi: 10.1016/j.anpedi.2020.04.023. Epub 2020 Jun 8.

[CAR-T immunotherapy in pediatric hemato-oncology… present and future]

[Article in Spanish]
Manel Juan  1 , Susana Rives  2
Affiliations
Editorial

[CAR-T immunotherapy in pediatric hemato-oncology… present and future]

[Article in Spanish]
Manel Juan et al. An Pediatr (Engl Ed). 2020 Jul.
No abstract available

PubMed Disclaimer

Figures

Figura 1
Figura 1
Producción y administración de células CART. Se obtienen los linfocitos del paciente mediante leucoaféresis. Ex vivo se separan los linfocitos T, se expanden y se modifican genéticamente para que expresen un receptor de células T quimérico (Chimeric antigen receptor) que reconoce un antígeno tumoral (CD19 en el caso de las CART19) y se reinfunden después al paciente.
See this image and copyright information in PMC

Comment on

  • [Immunotherapy with CAR-T cells in paediatric haematology-oncology].
    Mirones I, Moreno L, Patiño-García A, Lizeaga G, Moraleda JM, Toribio ML, Pérez-Martínez A; Grupo de Inmunoterapia y Terapias Avanzadas de la Sociedad Española de Hematología y Oncología Pediátricas; Grupo de Inmunoterapia y Terapias Avanzadas de la Sociedad Española de Hematología y Oncología Pediátricas. Mirones I, et al. An Pediatr (Engl Ed). 2020 Jul;93(1):59.e1-59.e10. doi: 10.1016/j.anpedi.2019.12.014. Epub 2020 Feb 24. An Pediatr (Engl Ed). 2020. PMID: 32107177 Spanish.

References

    1. Mirones I., Moreno L., Patiño A., Lizeaga G., Moraleda J.M., Toribio M.L. Inmunoterapia con células CAR-T en hemato-oncología pediátrica. An Pediatr (Barc) 2020;93:59.e1–59.e10. - PubMed
    1. Maude S.L., Laetsch T.W., Buechner J., Rives S., Boyer M., Bittencourt H. Tisagenlecleucel in Children and Young Adults with B Lymphoblastic Leukemia. N Engl J Med. 2018;378:439–448. - PMC - PubMed
    1. Castella M., Boronat A., Martín-Ibáñez R., Rodríguez V., Suñé G., Caballero M. Development of a Novel Anti-CD19 Chimeric Antigen Receptor: A Paradigm for an Affordable CAR T Cell Production at Academic Institutions. Mol Ther Methods Clin Dev. 2018;12:134–144. - PMC - PubMed
    1. Mussetti A., Maluquer C., Albasanz-Puig A., Gudiol C., Moreno-Gonzalez G., Corradini P. Handling the COVID-19 pandemic in the oncological setting. Lancet Haematol. 2020;piiS2352–3026:30108–30113. doi: 10.1016/S2352-3026(20)30108-3. - DOI - PMC - PubMed

Substances